Anti-androgen treatment of prostatic carcinoma may be a risk factor for development of rheumatoid arthritis

scientific article published in November 2002

Anti-androgen treatment of prostatic carcinoma may be a risk factor for development of rheumatoid arthritis is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID12415609

P2093author name stringJanet E Pope
Paul Hong
Mala Joneja
P433issue11
P407language of work or nameEnglishQ1860
P304page(s)2459-2462
P577publication date2002-11-01
P1433published inThe Journal of RheumatologyQ7743623
P1476titleAnti-androgen treatment of prostatic carcinoma may be a risk factor for development of rheumatoid arthritis
P478volume29

Reverse relations

cites work (P2860)
Q36355602Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice
Q55357541Androgen-Induced Immunosuppression.
Q51757080Association of tri-nucleotide (CAG and GGC) repeat polymorphism of androgen receptor gene in Taiwanese women with refractory or remission rheumatoid arthritis.
Q60955218Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence
Q35804435Rapid Anti-Inflammatory Effects of Gonadotropin-Releasing Hormone Antagonism in Rheumatoid Arthritis Patients with High Gonadotropin Levels in the AGRA Trial
Q37552575Short-term treatment with a gonadotropin-releasing hormone antagonist, cetrorelix, in rheumatoid arthritis (AGRA): a randomized, double-blind, placebo-controlled study
Q37155385Susceptibility to autoimmunity and B cell resistance to apoptosis in mice lacking androgen receptor in B cells

Search more.